Following encouraging fda feedback petros pharmaceuticals initiates self-selection (phase 2-equivalent) study for stendra

Important step towards stendra potentially becoming the first erectile dysfunction medication to successfully achieve otc status new york, ny / accesswire / october 19, 2023 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the-counter (otc) drug development programs, announces initiation of a self-selection study using the drug facts label (dfl) tested during its previously announced label comprehension study (lcs). fady boctor, petros' president and chief commercial officer, commented, "we continue to collaborate with the fda as we pursue an emerging pathway to expand access to stendra as the first potential otc prescription-grade therapeutic option for erectile dysfunction (ed).
PTPI Ratings Summary
PTPI Quant Ranking